289 related articles for article (PubMed ID: 29898217)
1. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
Rosen T; Albareda N; Rosenberg N; Alonso FG; Roth S; Zsolt I; Hebert AA
JAMA Dermatol; 2018 Jul; 154(7):806-813. PubMed ID: 29898217
[TBL] [Abstract][Full Text] [Related]
2. Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials.
Hebert AA; Albareda N; Rosen T; Torrelo A; Grimalt R; Rosenberg N; Zsolt I; Masramon X
J Drugs Dermatol; 2018 Oct; 17(10):1051-1057. PubMed ID: 30365584
[TBL] [Abstract][Full Text] [Related]
3. Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
Gropper S; Albareda N; Chelius K; Kruger D; Mitha I; Vahed Y; Gani M; García-Alonso F;
Future Microbiol; 2014; 9(9):1013-23. PubMed ID: 25340832
[TBL] [Abstract][Full Text] [Related]
4. Topical Ozenoxacin Cream 1% for Impetigo: A Review.
Schachner L; Andriessen A; Bhatia N; Grada A; Patele D
J Drugs Dermatol; 2019 Jul; 18(7):655-661. PubMed ID: 31334625
[TBL] [Abstract][Full Text] [Related]
5. Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo.
Gropper S; Cepero AL; Santos B; Kruger D
Future Microbiol; 2014; 9(8 Suppl):S33-40. PubMed ID: 25209523
[TBL] [Abstract][Full Text] [Related]
6. A review of the antibacterial activity of ozenoxacin.
Canton R; Chouinard L; Tarragó C
Future Microbiol; 2018 May; 13():1-2. PubMed ID: 29745241
[No Abstract] [Full Text] [Related]
7. Ozenoxacin: a review of preclinical and clinical efficacy.
Vila J; Hebert AA; Torrelo A; López Y; Tato M; García-Castillo M; Cantón R
Expert Rev Anti Infect Ther; 2019 Mar; 17(3):159-168. PubMed ID: 30686133
[TBL] [Abstract][Full Text] [Related]
8. Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
Torrelo A; Grimalt R; Masramon X; Albareda López N; Zsolt I
Dermatology; 2020; 236(3):199-207. PubMed ID: 31958794
[TBL] [Abstract][Full Text] [Related]
9. Ozenoxacin: A Novel Topical Quinolone for Impetigo.
Wren C; Bell E; Eiland LS
Ann Pharmacother; 2018 Dec; 52(12):1233-1237. PubMed ID: 29962213
[TBL] [Abstract][Full Text] [Related]
10. Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo.
Sahu JK; Mishra AK
Curr Drug Discov Technol; 2019; 16(3):259-264. PubMed ID: 29732990
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus.
Tarragó C; Esquirol LP; Arañó A; Lachamp L; D'Aniello F; Zsolt I
Future Microbiol; 2018 May; 13():21-30. PubMed ID: 29745240
[TBL] [Abstract][Full Text] [Related]
12. Ozenoxacin 1% cream (Xepi) for impetigo.
Med Lett Drugs Ther; 2019 Apr; 61(1570):63-64. PubMed ID: 31169810
[No Abstract] [Full Text] [Related]
13. Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo.
Schachner LA; Andriessen A; Benjamin LT; Claro C; Eichenfield LF; Esposito SM; Keller L; Kircik L; Kwong PC; McCuaig C
J Drugs Dermatol; 2021 Feb; 20(2):134-142. PubMed ID: 33538559
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
Canton R; Morrissey I; Vila J; Tato M; García-Castillo M; López Y; Gargallo-Viola D; Zsolt I
Future Microbiol; 2018 May; 13():3-19. PubMed ID: 29745242
[TBL] [Abstract][Full Text] [Related]
15. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
[TBL] [Abstract][Full Text] [Related]
16. Single-center, prospective, and observational study on the management and treatment of impetigo in a pediatric population.
Gatto A; Capossela L; Ferretti S; Di Sarno L; Oliveti A; Talamonti D; Curatola A; Chiaretti A; Fiori B
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9273-9278. PubMed ID: 37843341
[TBL] [Abstract][Full Text] [Related]
17. Ozenoxacin Cream, 1% - Topical Treatment of Impetigo.
Gupta AK; Versteeg SG; Abramovits W
Skinmed; 2017; 15(1):57-59. PubMed ID: 28270312
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial.
Koning S; van der Wouden JC; Chosidow O; Twynholm M; Singh KP; Scangarella N; Oranje AP
Br J Dermatol; 2008 May; 158(5):1077-82. PubMed ID: 18341664
[TBL] [Abstract][Full Text] [Related]
19. Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers.
Gropper S; Albareda N; Santos B; Febbraro S
Future Microbiol; 2014; 9(8 Suppl):S11-6. PubMed ID: 25209519
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus.
Tanus T; Scangarella-Oman NE; Dalessandro M; Li G; Breton JJ; Tomayko JF
Adv Skin Wound Care; 2014 Dec; 27(12):548-59. PubMed ID: 25396674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
